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1. Abstract 
1.1. Background: Evidence suggests that diabetes in all forms are on the rise especially gesta- 
tional diabetes mellitus which increases the risk of maternal and neonatal morbidities; however 
global prevalence rates and geographical distribution of GDM remain uncertain. The aim of 
this study is to examine the global burden of gestational diabetes mellitus. 
1.2. Methods: A systematic review and meta-analysis of studies reporting Randomised Clinical 
Trials (RCTs) in pregnant women who have GDM was conducted. Cochrane (Central), PubMed, 
Scopus, JBI, Medline, EMBASE and reference lists of retrieved studies were searched from in- 
ception to March 2019. Publications on prevalence of GDM irrespective of the baseline criteria 
used to diagnose GDM were included in the study. Studies were limited to English language, 
randomised control trials and women aged between 19 – 44 years inclusive. 
1.3. Results: Eleven RCTs met the inclusion criteria for this review. The included studies col- 
lectively reported GDM rates of 13,450 pregnant women from 7 countries. The diagnostic 
criteria used in the studies were World Health Organisation (WHO) 1985 and 1999, Interna- 
tional Association of Diabetes, Pregnancy Study Group (IADPSG), National Diabetes Data 
Group (NDDG), Carpenter–Coustan (C&C) and O'Sullivan's criteria. Seven RCTs screened 
for GDM in comparison with different diagnostic criteria in the same population while three 
studies used the same criteria for different groups. One study compared 100g, 3h OGTT to 
75g, 2h OGTT for diagnosing GDM using Carpenter and Coustan criteria. All seven RCTs that 
compared different diagnostic criteria in the same population detected different prevalence rates 
of GDM. Three RCTs measured prevalence of GDM in the same population using WHO 1999 
and IADPSG 2013 criteria. Using random effect model, data from three studies that compared 
IADPSG criteria to WHO 1999 showed an Odds Ratio (OR) of 0.52(0.15, 1.84), 95% Confi- 
dence Interval (CI) and high heterogeneity of 99%. In all three studies, prevalence of GDM 
measured by IADPSG criteria was higher than WHO 1999 criteria, although not significant (p= 
0.31). Combining all the studies gave a global estimated prevalence of GDM to be 10.13% (95% 
CI, 7.33 - 12.94) with moderate heterogeneity of 27%. The highest prevalence of GDM with 
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a median estimate of 38.25% (95% CI, 32.93 - 43.57) was reported 
in Kuala Lumpur while Ireland had the lowest prevalence 2.075 % 
(95% CI, 1.36–2.79). 
1.4. Conclusion: The results indicate that global burden of GDM 
is high, particularly in Southeast Asia. Applying different diagnostic 
criteria indicate that different group of women are identified; con- 
sequently, creating large differences in GDM prevalence even in the 
same population. 
2. Keywords: Gestational Diabetes Mellitus (GDM); Pregnan- 
cy-Induced diabetes; Prevalence 
3. Introduction 
Gestational Diabetes Mellitus (GDM) is defined as glucose intoler- 
ance with onset or first recognition during pregnancy. Although the 
mechanism is unclear, inadequate insulin production and or progres- 
sive insulin resistance as in the case of GDM has been attributed to 
a combination of increased maternal adiposity and insulin-desensi- 
tizing effects of placental hormones [1, 2]. It has been suggested 
that placental growth hormones, Human Placental Lactogen (HPL) 
and prolactin, play a major role in the onset of GDM by increasing 
maternal food intake, mobilising maternal nutrients for foetal growth 
and increasing insulin resistance to maternal nutrients [2]. Thus, pan- 
creatic beta cells increase their insulin secretion to compensate for 
the high glucose and insulin resistance caused, leading to defect in 
pancreatic beta cell function over time [1]. 
As at 2017, over 451 million people between the ages of 18 and 99 
were estimated to have diabetes worldwide. Out of this, approxi- 
mately 21.3 million were estimated to be women affected by some 
form of hyperglycaemia during pregnancy, of which 18.4 million of 
these cases were due to Gestational Diabetes Mellitus (GDM) [3]. 
This indicates that approximately 14% of pregnancies worldwide are 
affected by GDM yearly [3, 4]. It is instructive to note that out of 221 
data sources from 131 countries selected for the International Dia- 
betes Federation (IDF) diabetes atlas study, only 37 countries were 
reported to have data sources for GDM. Of these, only three were 
in Africa (Figure 1) [5]. 
For over a century, studies have shown that GDM causes grave ad- 
verse effects on pregnancy and foetal outcomes [1]. Back in 1882,   
a study by Matthews Duncan reported that 10 out of 19 maternal 
deaths which occurred at the time of labour or within a few weeks 
were due to diabetic coma caused by ‘diabetes antedating pregnancy’. 
This seminal study also reported that of the 27 pregnancies which 
were examined, abortion occurred in 6 cases, while 8 others had still- 
birth or death of babies shortly after birth. In all cases, the foetus- 
es and babies were unusually large sized (macrosomia) and affected 
by diabetes in one case [6, 7]. In the early 1940s, it was recognised 
that women who developed diabetes years after pregnancy had also 
previously experienced foetal and neonatal mortality. Successive re- 
search through to the contemporary era have made similar findings 
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of increased risk of foetal macrosomia, childhood obesity, as well as 
risk both women and children developing type 2 diabetes and other 
cardiovascular diseases [8, 9]. 
Until recently, the exact threshold for a diagnosis of GDM depends 
on the criteria used, and so far, there has been a lack of  consen-  
sus amongst health professionals. It is now advised by the ADA, the 
World Health Organization (WHO), the International  Federation 
of Gynaecology and Obstetrics, and the Endocrine Society, that the 
International Association of Diabetes and Pregnancy Study Group 
(IADPSG) criteria be used in the diagnosis of GDM [10]. The IAD- 
PSG criteria as summarised in Table 1, was developed based on the 
results of the Hyperglycaemia and Adverse Pregnancy Outcomes 
(HAPO) Study—a large multinational and multicentre study of 
23,000 pregnant women [11]. 
With the increasing epidemic of obesity and sedentary lifestyle, the 
global burden of GDM is predicted to increase, putting women of 
reproductive age and their babies at risk of intergenerational trans- 
mission of type 2 diabetes [12]. The literature on prevalence of 
GDM and risk of exposure to pregnant women is sparse and varied, 
particularly in Lower- and Middle-Income Countries (LMICs) where 
there is lack of national policies on the diagnosis and management 
of the disease. The objective of the present systematic review and 
meta-analysis was to investigate the global burden of gestational dia- 
betes mellitus by examining published data. 
Table 1: The IADPSG criteria for screening and diagnosis of Gestational diabetes 
 
Perform a 75-g oral glucose tolerance test (OGTT), with plasma glucose 
measurement fasting and at 1 and 2 h, at 24-28 of weeks gestation in women not 
previously diagnosed with overt diabetes. 
The OGTT should be performed in the morning after an overnight fast of at least 
8 h. 
The diagnosis of GDM is made when any of the following plasma glucose 
values are exceeded 
• Fasting: ≥92 mg/dl (5.1 mmol/l) 
• 1 h: ≥180 mg/dl (10.0 mmol/l) 
• 2 h: ≥153 mg/dl (8.5 mmol/l) 
 
Figure 1: Countries and territories with data sources reporting the prevalence of 
hyperglycaemia in pregnancy. Figure was adapted from International Diabetes Fed- 
eration report, 2017 [5]. 
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4. Methods 
4.1 Search Strategy 
EMBASE, MEDLINE, Cochrane CENTRAL, Scopus, PubMed, Jo- 
anna Briggs Institute (JBI), and Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) databases were searched from 
inception to week 6 March 2019 using a broad search strategy to 
identify all potentially relevant publications for this review. Broad 
keywords including Medical Subject Heading (MeSH) search terms 
“prevalence”, “epidemiology” and “frequency” were combined with 
terms that covered “GDM”, “Gestational diabetes mellitus”, “Preg- 
nancy-Induced Diabetes” and “Gestational Diabetes”. Grey litera- 
ture search as well as citation chaining was done to identify other 
relevant studies. 
4.2 Study Inclusion and Exclusion Criteria 
Original publications reporting on prevalence of GDM irrespective 
of the baseline criteria used to diagnose GDM were included in the 
study. Prevalence is defined as the percentage of existing cases of a 
disease in a given population at a particular time [13]. Studies were 
limited to English language, randomised control trials and women 
aged between 19 – 44 years inclusive. In terms of exclusion criteria, 
studies that reported prevalence of GDM only in a selective group 
such as women with obesity and those already at risk of developing 
type 2 diabetes were not included. 
4.3 Selection of Studies 
Titles and abstracts of studies retrieved from the databases were ini- 
tially screened. Full details of those that fulfilled the inclusion criteria 
were assessed and included in the study whereas duplicates and irrel- 
evant studies were excluded. Preferred Reporting Items for System- 
atic Reviews and Meta-Analyses (PRISMA) guidelines [14] was used 
for the study selection. 
4.4 Data Extraction 
Two review authors assessed the titles and abstracts of all articles 
identified from the database searches. Full texts of selected articles 
were retrieved and assessed independently for study eligibility. Dis- 
agreements were resolved through discussion or through consulting 
a third reviewer. 
4.5 Appraising the Quality of the Included Studies and Risk  
of Bias 
The quality of the eleven selected RCTs were assessed based on the 
Cochrane risk-of-bias tool criteria using three domains: randomisa- 
tion method, allocation concealment and blinding. The quality as- 
sessment was presented using the Review Manager 5.3 (RevMan). 
4.6 Data Analysis 
To measure heterogeneity or variability among studies, Chi-squared 
(Chi2) statistic was used. This was to assess whether differences in 
prevalence was due to sampling error or due to differences in sample 
 
populations. Prevalence data from all studies were pooled to get a 
single group summary using a random effect model. The meta-anal- 
yses results are presented using forest plots produced using RevMan 
and MS Excel (2016). 
5. Results 
A total of 17, 473 articles were identified from different databases 
and sources. Irrelevant studies were removed by assessing titles and 
abstracts. Removing duplicates and applying the inclusion criteria, 
53 studies were retrieved for a more detailed assessment of full text; 
from which 11 were found to be suitable for this review and 42 being 
excluded with reasons (Figure 2). 
 
 
Figure 2: Flowchart of search strategy and study selection process 
 
The included studies collectively reported GDM rates of 13,450 preg- 
nant women from seven countries under different health settings. 
Multiple published prevalence studies from some countries such as 
India (n=2), Thailand (n=2), Norway (n=2), and Ireland (n=2) based 
on various study populations and diagnostic criteria were retrieved, 
while others such as Malaysia, Nigeria and Turkey had single preva- 
lent studies. The studies were published from 1996 – 2018. Details 
of 11 studies included in this review are shown in Table2. 
About 75% of the selected studies had unclear risk of bias after qual- 
ity assessment using three domains: randomisation method, alloca- 
tion concealment and blinding (Figure 3). 4 out of the 11 included 
studies reported a method of randomisation: 
• Participants were randomised at their first visit to either se- 
lective screening when one or more risk factors were pres- 
ent or to universal screening (4). 
• Randomisation was generated by an independent research- 
er using the NQuery statistical software programme (ver- 
sion 2.0) (6). 
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• Randomisation was generated using a computer program 
(Random Number Generator Version 1.0 Segobit software, 
Issaquah, WA) (8). 
• Concealed randomisation was performed by independent 
researchers using a Web-based computerized procedure 
(11). 
Information on randomisation method for seven of the included 
studies were not provided (1, 2, 3, 5, 7, 9 and 10). 
Only one study had information on a method of allocation conceal- 
ment: 
• Sealed envelopes were used to assign participants after al- 
location sequence was generated using NQuery statistical 
software programme (version 2.0) (6). 
No clear information on allocation concealment was reported by the 
remaining 10 studies (1, 2, 3, 4, 5, 7, 8, 9, 10 and 11). 
Outcome assessment and analyses of glucose and insulin levels were 
performed blinded in (11). No clear information on blinding was 
reported by the remaining 10 studies (1, 2, 3, 4, 5, 6, 7, 8, 9 and 10) 
The primary outcome of concern was the prevalence of gestational 
diabetes in the population studied. The diagnostic criteria used in the 
studies were World Health Organisation (WHO) 1985 and 1999, In- 
ternational Association of Diabetes, Pregnancy Study Group (IAD- 
PSG), National Diabetes Data Group (NDDG), Carpenter–Coustan 
(C&C) and O'Sullivan's criteria (Figure 4). 
Seven RCTs (1, 2, 3, 5, 7, 8 and 9) screened for GDM in comparison 
with different diagnostic criteria in the same population while three 
studies (4, 6, and 11) used the same criteria for different groups. One 
study compared 100g, 3h OGTT to 75g, 2h OGTT for diagnosing 
GDM using Carpenter and Coustan criteria (10). Data from two or 
more studies that compared the same set of diagnostic criteria for 
GDM detection were combined for Meta-analyses. 
Three RCTs measured prevalence of GDM in the same population 
using WHO 1999 and IADPSG 2013 criteria. Using a random effect 
model, the data from (1, 2, and 5) were pooled for meta-analyses   
of GDM prevalence in 6, 307 participants (Figure 5). The result 
indicates an Odds Ratio (OR) of 0.52(0.15, 1.84), 95% Confidence 
Interval (CI) and high heterogeneity of 99%. In all three studies, 
prevalence of GDM measured by IADPSG criteria was higher than 
WHO 1999 criteria, although not statistically significant (p= 0.31). 
Using NDDG criteria, data from (4) indicated that universal screen- 
ing of pregnant women for GDM detected significantly higher prev- 
alence rate compared to selective risk-factor group (p <0.03). Con- 
versely, no significant difference was detected in GDM prevalence 
when pregnant women were screened either at a primary care facility 
(local General practice) or at a secondary health facility (p = 0.75) (6). 
Data from (11) also showed that receiving a 12-week standard exer- 
cise during pregnancy did not significantly affect GDM prevalence 
compared to women who received standard antenatal care (p = 0.52). 
Prevalence data from each study were averaged and the mean values 
combined using a random effect model for a group summary analysis 
following a guide for descriptive data analysis in MS Excel developed 
by [26]. Combining all the studies showed an estimated global GDM 
prevalence of 10.13 [95%CI 7.33 - 12.94] with moderate heterogene- 
ity of 27%. Overall, the highest prevalence of GDM with a median 
estimate of 38.25% (32.93 - 43.57%) was reported in Kuala Lumpur, 
Malaysia, followed by Punjab, India, Thailand, Turkey, and Nigeria 
(median prevalence 21.95, 14.25, 10.25, and 8.05%, respectively), 
whereas Ireland had the lowest prevalence (median 2.075 %; range 
1.36–2.79 %) (Figure 6). 
 
 
Figure 3: Summary of risk of bias: Presented as 
(a) each risk of bias item for each included study and 
(b) percentages across all included studies using RevMan 5.3. 
 
 
 
 
Figure 4: Different GDM diagnostic criteria used in the selected studies. 
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Table 2: Characteristics of studies included in this review. 
 
 First author and 
year 
City/Country Study setting Study participants/Sample size Period of study Diagnosis criteria Prevalence (%) Main outcomes 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
(Arora, Thaman et al. 
2015) 
[15]
 
 
 
 
 
 
 
 
 
 
 
Punjab/India 
 
 
 
 
 
 
 
 
 
Multistate and multi- 
departmental clinics 
 
 
 
 
 
 
5100 participants were randomly 
selected and screened for GDM of 
which 2179 urban (77.7%) and 
2921 rural (84.6%); Age ≤20 to 
≥30, mean age 21.5±3.3 years 
 
 
 
 
 
 
 
 
 
 
2009 - 2012 
 
 
WHO 1999; FPG level 
≥7.0 mmol/l (126 mg/ 
dl) or 2-h PG 
levels after a 75 g 
OGTT 
≥7.8 mmol/l (140 
mg/dl) 
 
 
 
 
 
9.00% 
1. 1014 declined participation. Main reason for declining participation was fear of GDM 
diagnosis as it is considered a social stigma. 
 
2. Applying both diagnostic criteria, GDM women had significantly higher FPG and 
2-h PG levels (P<0.001), increased BMI (P=0.01), were older (P<0.001) and shorter 
(P=0.01, WHO 2013; P<0.001, using WHO 1999) compared to non-GDM women. 
 
3. Percentage of women classified as having GDM was 7.2% by both criteria, 1.8% by 
the 1999 criteria only, and 27.7% by the 2013 criteria only. 
 
4. For prevalence according to risk factor, urban women had significantlyincreased 
GDM 
prevalence compared to rural women using both GDM 
criteria (P<0.001 for WHO 2013 and P=0.001 for WHO 
1999) 
WHO 2013 (IADPSG); 
FPG ≥5.1 mmol/L and/ 
or 1-h glucose ≥10.0 
mmol/L and/or 2-h ≥8.5 
mmol/L 
 
 
 
34.90% 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
(Basri, Mahdy et al. 
2018) 
[16]
 
 
 
 
 
 
 
 
 
 
 
 
 
Kuala Lumpur, 
Malaysia 
 
 
 
 
 
 
 
 
 
 
 
 
Antenatal clinic in a 
tertiary hospital and 
referral centre 
520 pregnant women with one 
or more risk factors for GDM at 
gestational age between 14 and 37 
weeks were randomly screened 
for GDM. Mean maternal age 
31.5±4.38 years. 
 
Included if any of the following 
were present: previous history of 
GDM, first degree relative with 
diabetes mellitus, obese body 
mass index (BMI) > 27, age 25 
years and above, current obstetric 
problem (essential hypertension, 
pregnancy induced hypertension, 
polyhydramnios, current use of 
steroids), previous macrosomic 
baby with birth weight ≥4.0 kg, 
previous unexplained still birth, 
foetus with congenital anomaly, 
 
 
 
 
 
 
 
 
 
 
 
 
 
2015 - 2017 
 
 
 
WHO 1999 (modified); 
FPG ≥6.1 mmol/L, 2 h 
≥7.8 mmol/L 
 
 
 
 
 
37.90% 
 
 
 
 
1. GDM prevalence using IADPSG (37.90%) and WHO (38.60%) diagnostic criteria. 
 
2. Prevalence rates obtained is 30% higher compared to the previously reported 18% 
and 24.9% by local studies. 
 
3. Reasons for high prevalence: 
a. the study setting is a referral centre hence more likely to receive high risk women 
b. all women age 25 years and above were considered high risk and part of the study 
 
4. GDM women diagnosed with WHO criteria had significantly increased incidences 
of gestational hypertension/pre-eclampsia (p=0.004) and neonatal hypoglycaemia 
(p=0.042) compared to those diagnosed with IADPSG while primary caesarean section 
(p=0.012) and foetal macrosomia (p=0.027) were significantly higher the IADPSG 
group 
 
 
 
 
 
IADPSG; FPG ≥5.1 
mmol/L, 2 h ≥8.5 
mmol/L 
 
 
 
 
 
 
 
38.60% 
 
 
 
 
 
 
 
3 
 
 
 
 
(Deerochanawong, 
Putiyanun et al. 
1996) 
[17]
 
 
 
 
 
 
 
Bangkok, 
Thailand 
 
 
 
 
 
 
Antenatal clinic of a 
tertiary hospital 
persistent glycosuria, recurrent 
urinary tract infection (UTI) or 
vaginal discharge 
709 pregnant women with a 
mean age of 26.9±5.6years. 
Subjects were randomly recruited 
from among women who were 
attending the antenatal clinic 
 
 
 
 
 
 
 
- 
National DiabetesData 
Group (NDDG); 100-g 
OGTT blood glucose 
≥ 5.8, 10.6, 9.2 and 
8.1 mmol/l of FPG 
levels at 1, 2 and 3 h, 
respectively 
 
 
 
 
1.40% 
 
 
 
 
1. Prevalence of GDM by WHO criteria in the same group of patients in this study was 
about 10 times higher than that using the NDDG criteria 
 
2. The sensitivity of GDM using NDDG and WHO criteria for detecting macrosomia 
was 21.4 and 42.9 %, and the sensitivity for detecting large for gestational age infants 
was 9.8 and 41.5 %, respectively. 
 
WHO 1999; 2-h plasma 
glucose after 75-g 
OGTT of 7.8 mmol/l 
 
 
15.70% 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
(Griffin, Coffey et 
al. 2000) 
[18]
 
 
 
 
 
 
 
 
 
 
 
 
 
Dublin, Ireland 
 
 
 
 
 
 
 
 
 
 
Outpatient obstetric 
clinic in a tertiary 
hospital 
3 152 pregnant women 
randomized at their first visit to 
either selective screening (1853, 
mean age 27.4±5.6), when one 
or more risk factors were present 
or to universal screening (1299, 
mean age 27.3±5.7). 
Risk factors for the selective 
group include; first degree 
relative with diabetesmellitus; 
>100 kg in current pregnancy; 
previous baby >4.5 kg; 
Previous unexplainedstillbirth/ 
intra-uterine death; previous 
major malformation; previous 
gestational diabetes mellitus; 
glycosuria in 2nd fasting urine 
sample; macrosomia in current 
 
 
 
 
 
 
 
 
 
 
 
 
- 
Risk factor group had 
a 3-h 100-g OGTT at 
32weeks (Standard 
hospital protocol) 
 
 
1.45% 
 
 
 
1. GDM prevalence detected in the selective group was significantly less than detected 
in the universal group (P< 0.03) 
 
 
 
 
 
The universal group 
had a 50-g GCT at 
26-28 weeks and if 
their plasma glucose at 
1 h was ≥7.8mmol/l, a 
formal 3-h 100-g OGTT 
was performed 
 
 
 
 
 
 
 
 
 
 
2.7%, 
 
2. GDM women were significantly older (p<0.05) in both groups (selective group = 
30.6±5.5 years; universal group = 31.0±5.6 years) than those without GDM (27.0±5.7 
years) 
 
3. Universal screening of GDM led to a higher rate of spontaneous vaginal delivery   
at term (77.0%), and lower rates of macrosomia (0.0%), Caesarean section (11.4%), 
pre-eclampsia (0.0%) and admission to neonatal intensive care unit (2.9%) compared 
to selective screening: lower rate of spontaneous vaginal delivery at term (56.0%), and 
higher rates of macrosomia (11.1%), Caesarean section (18.5%), pre-eclampsia (14.8%) 
and admission to neonatal intensive care unit (18.5%) 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
(Helseth, Salvesen et 
al. 2014)
[19]
 
 
 
 
 
 
 
 
 
 
Trondheim/ 
Stavanger, 
Norway 
 
 
 
 
 
 
 
 
 
 
 
Tertiary hospital 
pregnancy; polyhydramnios in  
 
 
 
 
 
 
 
 
 
 
2007 - 2009 
WHO 1999; FPG ≥7.0  
 
 
6.1% (42/687) 
 
current pregnancy mmol/L and/ or 2-h  
Study population was extracted 
from a previously reported 
plasma glucose ≥7.8 
mmol/L either at 18 – 
 
1. GDM prevalence was 0.4% according to the WHO criteria at 18 – 22 weeks and 5.7% 
randomized controlled trial (RCT) 22 weeks and/or 32 – 36 at 32 – 36 weeks, while GDM prevalence was 2.6% and 4.8% according to simplified 
assessing the effect of regular 
weeks. 
IADPSG criteria at same time points. IADPSG criterion is sensitive to detect GDM 
exercise during pregnancy on the 
incidence of GDM. 687 women 
with mean age of 30.6±4.2years 
were selected to be screened with 
 
early which may reduce the short or long-term burden of GDM in mother or child. 
 
2. Maternal age was the only risk factor that was independently associated with both 
WHO (p=0.008) and IADPSG (p=0.002) criteria indicating each criterion identify 
 
 
 
Simplified IADPSG; 
 
 
 
 
 
 
7.4% (51/687 
both WHO 1999 and simplified FPG ≥5.1 mmol/L and/ different group of women. 
IADPSG criteria. 89.7% of or 2-h plasma glucose  
the participants were college/ ≥8.5 mmol/L at the 3. Only 27% of GDM women fulfilled both criteria for GDM. 
university educated same time points.  
2020, V1(3): 1-10 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
 
 
(O'Dea, Tierney et al. 
2016)
[20]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Galway, Ireland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three hospital sites 
 
781 were recruited and 
randomised to have screening 
completed either in primary care 
(n= 391) or secondary care (n= 
390). 215 women received their 
GDM screen in primary care 
while 475 women received their 
screen in secondary care. 
The primary care group were 
screened for GDM at their local 
general practitioner (GP) clinic 
while secondary care group were 
screened at the hospital site at 
which they attended for ante- 
natal care. 
 
An independent researcher was 
responsible for generating the 
allocation sequence using the 
NQuery statistical software 
programme (version 2.0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IADPSG 
 
 
 
 
6.5%, primary 
care (n = 215) 
 
 
 
 
 
 
 
 
 
 
1. significant difference between Primary care group (32.5±5.0) and Secondary care 
group (33.5±5.0) in terms of maternal age at delivery (p= 0.02) 
 
2. No significant differences (p= 0.75) in GDM prevalence between primary care (6.5%) 
and secondary care (7.2%). 
 
3. Mean days to begin specialist ante-natal diabetes care for the primary care group 
was longer (23.6 days) compared to 18.9 days for the secondary care group, though 
statistically not significant (p=0.09). 
 
 
 
 
 
 
 
 
 
7.2%, secondary 
care (n = 475) 
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
(Olarinoye, 
Ohwovoriole et al. 
2004)
[21]
 
 
 
 
 
 
 
 
 
 
 
Lagos, Nigeria 
 
 
 
 
 
 
 
 
 
 
Tertiary hospital 
 
 
 
 
 
 
 
248 pregnant women in their 
3
rd 
trimester with mean age of 
30.7±4.2 years were randomly 
selected for 75g (n=138) or 100g 
OGTT (n=110). 
 
 
 
 
 
 
 
 
 
 
1997-1999 
WHO (1985) criteria 
75g OGTT; FPG 
≥105mg/dl; 2-h plasma 
glucose ≥165mg/dl 
 
 
 
11.60% 
 
 
1. No significant differences in age (p=0.93), parity (p=0.27), BMI (p=0.33) and 
presence of risk factors (p=0.75) between the two groups. 
 
2. Prevalence rate of GDM detected by WHO 1985 (11.6%) and NDGG 1979 (4.6%) 
criteria were significantly different (p=0.04). 
 
3. Out of the 248 participants, 8.5% were diagnosed of GDM by either criterion. 
 
 
4. 31.3% of women diagnosed of GDM by either criterion had foetal macrosomia while 
11.3% non-GDM women had foetal macrosomia (p=0.01) 
National Diabetes 
Data Group (NDDG) 
(1979) criteria for 100g 
OGTT; FPG ≥105mg/ 
dl; 1-h plasma glucose 
≥190mg/dl; 2-h plasma 
glucose ≥165mg/dl; 
3-h plasma glucose 
≥145mg/dl 
 
 
 
 
 
 
 
4.50% 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
 
 
(Sevket, Ates et al. 
2014)
[22]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Istanbu, Turkey 
 
 
 
Tertiary hospital 
 
 
 
 
786 Participants were randomized 
into two groups using a computer 
program (Random Number 
Generator Version 1.0 Segobit 
software, Issaquah, WA). Group 
I (n=386, mean age 28.0±4.9), 
had one-step method (2-h, 75 g 
OGTT) while Group 2 (N=400; 
mean age 28.5±5.0) underwent 
the two-step method, a 50 g GCT 
at 24–28 weeks of gestation. 
Those with positive results (140 
mg/dl) then underwent a 100 
g OGTT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2011-2012 
IADPSG; FPG ≥5.1 
mmol/l, 1-h plasma 
glucose ≥10.0 mmol/l 
or a 2-h plasma glucose 
≥8.5 mmol/l 
 
 
 
14.5% 
1. Maternal demographic variables; Mean maternal age (p=0.171), BMI (p=0.09), 
history of previous macrosomic delivery (p=0.903) and Positive family history 
(p=0.057) were not statistically significant between Group 1 and Group 2 
 
2. Prevalence of GDM was significantly higher in Group 1 (14.5%) verses Group 2 
(6.0%) (p<0.001) 
 
3. Non-GDM women detected in Group 1 (IADPSG-negative group) had significantly 
lower incidence of pre-eclampsia, macrosomia polyhydramnios, large for gestational 
age and greater infant birthweight (p<0.05) than the Non-GDM women in Group 2 
(GCT-negative and the C&C-negative groups). 
 
4. IADPSG criteria is more sensitive for prenatal GDM screening and women defined 
as having normal glucose tolerance by IADPSG criteria had better perinatal outcomes 
than the other criteria. 
  
 
 
 
 
Carpenter–Coustan 
(C&C); FPG ≥ 
95mg/dl; 1-h plasma 
glucose ≥180mg/dl; 
2-h ≥155mg/dl; 3-h 
≥140mg/dl 
 
 
 
 
 
 
 
 
 
6% 
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(Somani, Arora et al. 
2012)[23] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maharashtra, 
India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tertiary hospital 
 
 
 
 
 
 
 
 
 
 
 
 
 
723 pregnant women with 
mean age of 23.45 years; were 
screened randomly for GDM 
at 24–28 weeks gestation using 
O'Sullivan's, Carpenter and 
Coustan's and WHO 1999 criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 
WHO 1999; FPG level 
≥7.0 mmol/l (126 mg/ 
dl) or 2-h PG 
levels after a 75 g 
OGTT 
≥7.8 mmol/l (140 
mg/dl) 
 
 
 
 
4.80% 
 
 
 
 
 
 
 
 
 
1. The least GDM prevalence was detected by O’Sullivan’s criteria (3.45%) compared 
to WHO (4.8%) and C&C (6.36%) 
 
2. Women with past history of abortion had significantly higher percentage of GDM 
(p=0.05) by O’Sullivan’s criteria (40%) than WHO criteria (25.7%) 
 
3. Women positive for GDM by O’Sullivan’s criteria had the highest relative risk 
of abnormal delivery (RR=1.93, CI= 0.84–4.39) compared to WHO (RR=1.39, 
CI=0.43–4.48) and C&C (RR=1.17, CI=0.51–2.71), although the differences were not 
statistically significant 
Carpenter and Coustan's 
(C&C); FPG ≥ 
95mg/dl; after 100g 
OGTT, 1-h plasma 
glucose ≥180mg/dl; 
2-h ≥155mg/dl; 3-h 
≥140mg/dl 
 
 
 
 
6.36% 
 
 
O'Sullivan's; 100g 
OGTT; FPG ≥105mg/ 
dl; 1-h plasma 
glucose ≥190mg/dl; 
2-h ≥165mg/dl; 3-h 
≥145mg/dl 
 
 
 
 
 
 
 
3.50% 
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(Soonthornpun, 
Soonthornpun et al. 
2003)
[24]
 
 
 
 
 
 
Thailand 
 
 
 
 
 
- 
42 pregnant women with 50g 
GCT values ≥140mg/dl and 
between 14- and 36-weeks’ 
gestation were randomly selected 
for both 75g and 100g OGTT 
within 1-week interval. Mean 
maternal age 33.6±5.4 
 
 
 
 
 
- 
Carpenter and Coustan’s 
(C&C); FPG ≥ 
95mg/dl; after 100g 
OGTT, 1-h plasma 
glucose ≥180mg/dl; 
2-h ≥155mg/dl; 3-h 
≥140mg/dl 
 
21.4%, 100-g, 
3-h OGTT 
1. The interval between 75g and 100g OGTT was 3.8±1.5 days 
 
 
2. GDM prevalence using the C&C and 100g OGTT criteria (21.4%) was higher than 
using the same C&C criteria for 75g OGTT (7.1%), though the difference was not 
statistically significant (OR, 0.28; 95% CI, 0.07-1.13; P=0.06). 
 
3. The mean plasma glucose concentrations at 1, 2, and 3 h during the 100g OGTT was 
significantly higher than those during 75g OGTT (P<0.05) 
7.1%, 75-g, 2-h 
OGTT 
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(Stafne, Salvesen et 
al. 2012)[25] 
 
 
 
 
 
 
 
 
 
Trondheim/ 
Stavanger, 
Norway 
 
 
 
 
 
 
 
 
 
 
 
Tertiary hospitals 
 
 
702 pregnant women booking 
appointments for routine 
ultrasound scans at participating 
hospitals were recruited and 
randomly assigned to receiving 
a 12-week standard exercise 
program (intervention group; 
n=375, mean age 30.5±4.4 years) 
or standard antenatal care (control 
group; n=327, mean age 30.4±4.3 
years). Concealed randomization 
was performed by independent 
researchers using a Web-based 
computerized procedure. 
 
 
 
 
 
 
 
 
 
 
 
2007- 2009 
 
 
 
 
 
 
WHO 1999 criteria; 
fasting glucose level 
in fasting whole blood 
≥6.1 mmol/L, or plasma 
glucose ≥7.0 mmol/L, 
or 2-hour value ≥7.8 
mmol/L 
 
 
 
 
 
 
 
 
 
7%, (intervention 
group) 
 
 
 
 
1. The groups had similar baseline characteristics, except insulin resistance, which was 
lower in the intervention group (10.1±5.42 IU/mL) than the control group (10.7±5.47 
IU/mL) 
 
2. No significant differences in the prevalence of gestational diabetes between groups; 
25 of 375 (7%, 95% CI 4.3–9.7) intervention group women compared with 18 of 327 
(6%, 95% CI 3.3– 8.6) control group women (P=0.52). 
 
3. pregnancy outcomes were not significantly different between the two groups; 
Gestational age at birth (p=0.22), preeclampsia (p>0.99), caesarean delivery (p=0.58) 
6%, (control 
group) 
 
 
Figure 5: Forest plot showing a comparison between WHO 1999 and IADPSG 2013 diagnostic criteria 
 
Figure 6: Forest plot showing estimated summary of GDM prevalence from selected studies 
6. Discussion 
Gestational diabetes mellitus is a global public health concern with 
adverse implications for the mother and her offspring. There are 
varying reported global prevalence rates of GDM partly due to dif- 
ferences in screening and diagnostic criteria as well as differences in 
race-specific risk factors [27, 28]. This review explored the global 
prevalence rates of GDM and its diagnosis. 
Among the 11 included studies for this review, seven different criteria 
were employed for GDM diagnosis. Compared to selective screen- 
ing, Griffin, M. E., et al. (2000) identified that universal screening of 
all pregnant women for GDM detected significant number of 
positive cases (p< 0.03) [18]. Universal screening led to a higher rate 
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of spontaneous vaginal delivery at term (77.0%), lower rates of 
Caesarean section (11.4%), and fewer admission to neonatal 
intensive care unit (2.9%) compared to selective screening: 
spontaneous vaginal de- livery at term (56.0%), Caesarean section 
(18.5%), and admission to neonatal intensive care unit (18.5%) [4]. 
Notwithstanding the cost effectiveness of selective screening [29], 
this study is in support of literature that relying on risk factors for 
GDM screening is less sensitive and could potentially miss about 
40% of GDM cases [30-32]. 
The most commonly used diagnostic criterion was WHO 1999 (33%) 
followed by IADPSG (28%) with O’Sullivan and WHO 1985 criteria 
being the least (6% each). The optimum criterion for GDM diagnosis 
is still under debate worldwide, resulting in different approach being 
endorsed by different stakeholders and countries [32-35]. Within the 
same population, there were variations of prevalence estimates based 
on the diagnostic criteria used. The highest variation was recorded in 
Punjab, India, where the prevalence estimates ranged from 9.00% to 
34.90% based on WHO 1999 and IADPSG criteria respectively (1). 
Likewise, in Bangkok, Thailand, GDM prevalence estimates varied 
from 1.40% to 15.70% based on NDDG and WHO1999 criteria re- 
spectively (3). Similar trend of wide variations in GDM prevalence 
detected by different diagnostic criteria were observed in Norway 
(5), Nigeria (7), Turkey (8), and Maharashtra, India (9), while the 
least variation was reported in Kuala Lumpur, where WHO 1999 
and IADPSG criteria detected prevalence rates of 37.90% and 38.6% 
respectively (2). Variation in the incidence and prevalence rates of 
GDM in the same population due to different diagnostic criteria have 
been previously reported, with its impact on prenatal outcomes and 
health costs still under discussion [36, 37]. 
Compared with different diagnostic criteria, IADPSG consistently 
produced higher prevalence rates of GDM than other criteria when 
applied in the same population with similar maternal demographic 
variables (1, 2, 5 and 8). This is not surprising as IADPSG compar- 
atively has lower threshold value of fasting glucose (5.1 mmol/L) 
compared to WHO1999 (7.0 mmol/L), NDDG (5.8 mmol/L), and 
Carpenter-Coustan (5.3 mmol/L) criteria [32]. Although IADPASG 
criterion has demonstrated higher sensitivity for GDM detection 
with associated fewer adverse outcomes for both mother and child 
[32, 36, 38], its potential to overestimate GDM burden in a pop- 
ulation which will consequently inform health policy is a concern. 
Again, it is thought that over-diagnosis of GDM could predispose 
women to psychological stress, unnecessary treatments and impaired 
quality of life [37]. 
Notwithstanding the type of diagnostic criteria used, the pooled 
global prevalence of GDM from the included studies was 10.13 
[95% CI 7.33 - 12.94]. With majority of the included studies from 
Southeast Asia, our reported global prevalence is comparable to an- 
other study which reported the pooled prevalence of GDM in this 
region as 10.1% (95% CI 6.5–15.7%) [39]. Our study supports the 
IDF atlas report that circa 14% of pregnancies are affected by GDM 
 
globally [3], and accordingly call for more attention and intervention. 
7. Conclusion 
There are several risk factors that contribute to the onset of GDM, 
and from our study increased maternal Body Mass Index (BMI) and 
age were reported to be significantly higher in women diagnosed with 
GDM compared to non-GDM women (1, 5). In addition to the un- 
derlying risk factors, prevalence estimates of GDM in a population 
may be influenced by the type of diagnostic criteria employed. Dif- 
ferent fasting plasma glucose cut-off points used by the individual di- 
agnostic criteria means that different group of women are identified; 
thus, creating large differences in GDM prevalence even in the same 
population. Consequently, care should be taken when interpreting 
prevalence estimates of GDM within a country and across a region. 
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